Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 5/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345531 | 1.00 | RORC (0.38) | RORCGRIA4ADAM17MMP2MMP9 | |
| SCHEMBL6350001 | 1.00 | RORC (0.38) | RORCGRIA4ADAM17MMP2MMP9 | |
| SCHEMBL6345809 | 0.88 | RORC (0.46) | RORCADAM17MMP2MMP9MMP13 | |
| SCHEMBL6354891 | 0.88 | RORC (0.46) | RORCADAM17MMP2MMP9MMP13 | |
| SCHEMBL6345808 | 0.88 | RORC (0.46) | RORCADAM17MMP2MMP9MMP13 | |
| SCHEMBL6347105 | 0.88 | ADAM17 (0.38) | RORCGRIA4ADAM17MMP2MMP9 | |
| SCHEMBL6345535 | 0.86 | RORC (0.38) | RORCADAM17MMP2MMP9MMP14 | |
| SCHEMBL6240195 | 0.85 | ADAM17 (0.39) | RORCGRIA4ADAM17MMP2MMP9 | |
| SCHEMBL6348039 | 0.85 | ADAM17 (0.39) | RORCGRIA4ADAM17MMP2MMP9 | |
| SCHEMBL6344031 | 0.85 | ADAM17 (0.39) | RORCGRIA4ADAM17MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | claimed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | claimed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | claimed |
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | RORC 2136/4885GRIA4 15/4885ADAM17 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.